Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors.
Thirteen patients with cisplatin-refractory germ cell tumors were treated on a Phase II trial with pyrazoloacridine. Pyrazoloacridine was given intravenously at 600 mg/m2 every three weeks. The median nadir leucocyte count was 2.5 cells/mm3, hemoglobin was 10.8 g/dl, and platelet count was 126,000 cells/m3. None of the thirteen evaluable patients achieved a major response. Pyrazoloacridine is not efficacious in the treatment of cisplatin-refractory germ cell tumors.
Vuky
J
J
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
McCaffrey
J
J
Ginsberg
M
M
Mariani
T
T
Bajorin
D F
DF
Bosl
G J
GJ
Motzer
R J
RJ
D000166:Acridines / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D018237:Germinoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008479:Mediastinal Neoplasms / Q000188:drug therapy; D008875:Middle Aged; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D013736:Testicular Neoplasms / Q000188:drug therapy
D000166:Acridines; D000970:Antineoplastic Agents; D011720:Pyrazoles; C064541:NSC 366140; D002945:Cisplatin